TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18663294

Group type: EXPERIMENTAL
Intervention: DPOAE Protocol P1 (L(1) = 60, L(2) = 50 dB SPL)
Number of subjects: 1550

Group type: EXPERIMENTAL
Intervention: DPOAE Protocol P2 (L(1) = 65, L(2) = 55 dB SPL)
Number of subjects: 1550

Group type: EXPERIMENTAL
Intervention: DPOAE Protocol P3 (L(1) = 75, L(2) = 65 dB SPL)
Number of subjects: 1550

Group type: COMPARATOR
Intervention: Standard TEOAE test
Number of subjects: 1550
Study: 16581481

Group type: COMPARATOR
Intervention: Doppler tissue imaging (DTI)
Number of subjects: 131
Study: 14681716

Group type: EXPERIMENTAL
Intervention: hyperosmolality induced by fluid restriction and intravenous infusion of hypertonic NaCl (2‐5%, wt/vol) during 17 h
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: hypo‐osmolality produced by intravenous administration of desmopressin, liberal water drinking and infusion of hypotonic saline (0.4%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: iso‐osmolality study with oral water intake ad libitum
Number of subjects: 10
Study: 11211636

Group type: EXPERIMENTAL
Intervention: Behavioral counseling
Number of subjects: 883

Group type: COMPARATOR
Intervention: Usual health promotion
Number of subjects: 883
Study: 9089663

Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin type A (BoNt/A) preparation 1 injected into the left foot
Number of subjects: 0

Group type: COMPARATOR
Intervention: Botulinum neurotoxin type A (BoNt/A) preparation 2 injected into the right foot
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both preparations (1 and 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower concentrations of toxin
Number of subjects: 0
Study: 7933838

Group type: EXPERIMENTAL
Intervention: recombinant human IGF-I (rhIGF-I) (100 micrograms/kg body wt subcutaneously twice daily) - short-term treatment (4 days)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: recombinant human IGF-I (rhIGF-I) (100 micrograms/kg body wt subcutaneously twice daily) - long-term treatment (13-27 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 9
Study: 3220789

Group type: EXPERIMENTAL
Intervention: Single volume exchange transfusion (ET; 80 ml/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Double volume exchange transfusion (ET; 160 ml/kg)
Number of subjects: 20
Study: 1985161

Group type: EXPERIMENTAL
Intervention: Short arm (2 additional courses; 5 weeks)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Long arm (5 additional courses with 2 additional drugs; 16 weeks)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Both treatment arms (short and long)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Short arm
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 216
Study: 872103

Group type: EXPERIMENTAL
Intervention: Transurethral resection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Segmental resection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radical cystectomy with pelvic lymphadenectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cystectomy with preoperative adjuvant radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative irradiated patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy and/or immunotherapy
Number of subjects: 0
Study: 31613945

Group type: EXPERIMENTAL
Intervention: SRP + PDT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SRP + LLLT
Number of subjects: 0

Group type: COMPARATOR
Intervention: SRP alone (Control)
Number of subjects: 0
Study: 29065916

Group type: EXPERIMENTAL
Intervention: Sertraline starting at 50 mg daily for 1 week, increasing to 100 mg daily for up to 11 weeks (with the option of increasing to 150 mg if required)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study: 26018127

Group type: EXPERIMENTAL
Intervention: Exercise intervention (specific details not provided)
Number of subjects: 1104
Study: 24020866

Group type: EXPERIMENTAL
Intervention: Naloxone (3.2 mg/70 kg body weight)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 20652572

Group type: EXPERIMENTAL
Intervention: 27-gauge pencil-point (PP) spinal needle
Number of subjects: 363

Group type: COMPARATOR
Intervention: 27-gauge Quincke (Q) spinal needle
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Pre-operative time in upright sitting position (10 min or 30 min)
Number of subjects: 363
Study: 19701110

Group type: EXPERIMENTAL
Intervention: Pemetrexed at 750 mg/m2 every 21 days with weekly cetuximab at 250 mg/m2
Number of subjects: 36

Group type: COMPARATOR
Intervention: Historical controls of either single agent
Number of subjects: 36
Study: 18000101

Group type: EXPERIMENTAL
Intervention: Significant other primes (e.g., mother, roommate)
Number of subjects: 0
Study: 12849651

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors with thrombolytic agents
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Combination therapy with GP IIb/IIIa inhibitors and thrombolytic agents
Number of subjects: 3000
Study: 10825327

Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 17

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 17
Study: 8992880

Group type: EXPERIMENTAL
Intervention: Unilateral high-resistance strength training for 12 months
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Detraining for 8 months
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (Nineteen students, mean 25.7 +/- 5.2 yrs, 165 +/- 4 cm, 62.1 +/- 7.0 kg)
Number of subjects: 13
Study: 1737315

Group type: EXPERIMENTAL
Intervention: Standard medical care plus MTC services
Number of subjects: 267

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 267
Study: 6392170

Group type: EXPERIMENTAL
Intervention: Hexabrix 32%
Number of subjects: 10

Group type: COMPARATOR
Intervention: Renografin-60
Number of subjects: 10
Study: 30764549

Group type: EXPERIMENTAL
Intervention: Educational intervention in Nutrition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational intervention in WASH/Malaria
Number of subjects: 0
Study: 29050702

Group type: EXPERIMENTAL
Intervention: Presence of fragmented QRS (fQRS) in ECG
Number of subjects: 127

Group type: COMPARATOR
Intervention: Absence of fragmented QRS (fQRS) in ECG
Number of subjects: 127
Study: 25627874

Group type: EXPERIMENTAL
Intervention: Uric acid
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study: 23479062

Group type: EXPERIMENTAL
Intervention: Family-centered advance care planning (ACP) intervention including 3- to 60-minute sessions 1 week apart, Lyon Family-Centered ACP Survey, Respecting Choices interview, and Five Wishes.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Family-centered advance care planning (ACP) intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care plus information (Control)
Number of subjects: 60
Study: 21473764

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg per day)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Inhaled beclometasone (400 μg per day) with atorvastatin
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 19015209

Group type: EXPERIMENTAL
Intervention: Full information programme (group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Full information programme (group 2)
Number of subjects: 60
Study: 17110581

Group type: EXPERIMENTAL
Intervention: Reminders of money
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Participants primed with money
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nonmoney reminders
Number of subjects: 9

Group type: COMPARATOR
Intervention: Neutral concepts
Number of subjects: 9
Study: 15373816

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 10769276

Group type: EXPERIMENTAL
Intervention: Ciprofibrate therapy
Number of subjects: 20
Study: 9068936

Group type: EXPERIMENTAL
Intervention: Sertraline tablets (morning administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertraline tablets (evening administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertraline tablets (with food)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertraline tablets (without food)
Number of subjects: 0
Study: 8415147

Group type: EXPERIMENTAL
Intervention: Guided imagery in addition to standard antiemetic regimen
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard antiemetic regimen
Number of subjects: 28
Study: 2951804

Group type: EXPERIMENTAL
Intervention: Fenoterol (200 micrograms)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (80 micrograms)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Duovent (fenoterol 200 micrograms + ipratropium bromide 80 micrograms)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31640770

Group type: EXPERIMENTAL
Intervention: Home visit care plus group antenatal care
Number of subjects: 671

Group type: COMPARATOR
Intervention: Home visit care
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 671
Study: 28302952

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1095
Study: 25786565

Group type: EXPERIMENTAL
Intervention: SRP plus 1.2 mg rosuvastatin gel
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 22773192

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 98
Study: 21703001

Group type: EXPERIMENTAL
Intervention: Patient education integrated with acupuncture (two parts: self-care education in four weekly 50-minute sessions and eight weekly 50-minute acupuncture sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 18304817

Group type: EXPERIMENTAL
Intervention: Mitek bone‐tendon‐bone cross pin (RIGIDfix)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Linvatec Bioscrew (control device)
Number of subjects: 40
Study: 16875647

Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (100 mg every 4 hours)
Number of subjects: 101
Study: 12771322

Group type: EXPERIMENTAL
Intervention: Functional oil (FctO)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Olive oil (OL)
Number of subjects: 24
Study: 11460607

Group type: EXPERIMENTAL
Intervention: Test Dentifrice (containing pyrophosphate, tripolyphosphate and a copolymer in a 0.243% sodium fluoride/silica base)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Positive Control Dentifrice (containing tetrapotassium pyrophosphate, disodium pyrophosphate, and tetrasodium pyrophosphate in a 0.243% sodium fluoride/silica base)
Number of subjects: 89
Study: 9218950

Group type: EXPERIMENTAL
Intervention: Early amniocentesis (11-12 weeks of gestation)
Number of subjects: 695

Group type: COMPARATOR
Intervention: Midtrimester amniocentesis (15-16 weeks of gestation)
Number of subjects: 695
Study: 8077314

Group type: EXPERIMENTAL
Intervention: Flax seed ingestion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 18
Study: 3318455

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 21
Study: 29934374

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 3851

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3851
Study: 28251319

Group type: EXPERIMENTAL
Intervention: computer dynamic posturography (CDP) training
Number of subjects: 139

Group type: COMPARATOR
Intervention: control group
Number of subjects: 139
Study: 25667122

Group type: EXPERIMENTAL
Intervention: Rocuronium (0.9 mg kg(‐1))
Number of subjects: 80
Study: 23547488

Group type: EXPERIMENTAL
Intervention: Crest PRO‐HEALTH Rinse (CPH)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Cēpacol (C)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Scope (S)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Viadent ADVANCED CARE (V)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Brushing alone (BA)
Number of subjects: 171
Study: 21908961

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SA) with 3 ml of 0.75% ropivacaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Combined sciatic/lumbar plexus nerve block (CSLPB) with 10 ml 0.75% ropivacaine and 10 ml of normal saline (20 ml total)
Number of subjects: 50
Study: 17507641

Group type: EXPERIMENTAL
Intervention: Additional body weight‐supported treadmill training for 4 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: General physical therapy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Additional body weight‐supported treadmill training
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Additional gait training
Number of subjects: 14
Study: 17157760

Group type: EXPERIMENTAL
Intervention: Hospice Group
Number of subjects: 864

Group type: COMPARATOR
Intervention: Community Group
Number of subjects: 864

Group type: COMPARATOR
Intervention: Pain prevalence method
Number of subjects: 864

Group type: COMPARATOR
Intervention: Pain Management Index (PMI)
Number of subjects: 864
Study: 14622081

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluoxetine plus self-exposure (FLU + SE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo plus self-exposure (PLA + SE)
Number of subjects: 60
Study: 11060940

Group type: EXPERIMENTAL
Intervention: Attending to pain-related thoughts
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Suppressing pain-related thoughts
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (thinking about anything)
Number of subjects: 39
Study: 7588456

Group type: EXPERIMENTAL
Intervention: Thyroxine treatment
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Patients receiving long-term anticonvulsant therapy
Number of subjects: 35
Study: 2121394

Group type: EXPERIMENTAL
Intervention: GnRH agonist (buserelin) 100 micrograms
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: hCG 50 IU/kg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 14
Study: 582772

Group type: EXPERIMENTAL
Intervention: 0.1 mg WE 941
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.3 mg WE 941
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.5 mg WE 941
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 30 mg flurazepam
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31621850

Group type: EXPERIMENTAL
Intervention: Generalized linear models with variable selection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Models developed from one country and validated in another
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical models applied to Year‐3 data
Number of subjects: 0
Study: 31093942

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention programme (CATI)
Number of subjects: 0
Study: 27810347

Group type: EXPERIMENTAL
Intervention: Percutaneous Mechanical Circulatory Support (pMCS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intra-Aortic Balloon Pump (IABP)
Number of subjects: 48
Study: 24460003

Group type: EXPERIMENTAL
Intervention: Culturally targeted breast cancer screening educational intervention (n = 147)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Mammography screening brochure published by the National Cancer Institute (n = 153)
Number of subjects: 300
Study: 23299013

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV-6/11/16/18 vaccine
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 700
Study: 21689206

Group type: EXPERIMENTAL
Intervention: Rotational technique
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 78
Study: 18685531

Group type: EXPERIMENTAL
Intervention: Electrically stimulated eccentric exercise (STIM)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Voluntary eccentric exercise (VOL)
Number of subjects: 16
Study: 16515419

Group type: EXPERIMENTAL
Intervention: Urge incontinence
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Abnormal daytime sleepiness
Number of subjects: 782
Study: 12721239

Group type: EXPERIMENTAL
Intervention: Exercise training on cycle ergometers three times per week for 15 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 53
Study: 11525594

Group type: EXPERIMENTAL
Intervention: Fresh broccoli (200 g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Steamed broccoli (200 g)
Number of subjects: 12
Study: 9422300

Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8288160

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (15 mg twice daily for 8 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (9 obese patients)
Number of subjects: 18
Study: 3550084

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 29536609

Group type: EXPERIMENTAL
Intervention: Dedicated Axxess bifurcation stent and Biomatrix stents
Number of subjects: 40

Group type: COMPARATOR
Intervention: Culotte stenting using Xience stents
Number of subjects: 40
Study: 27863277

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4000 IU/d for 28 days)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Resistance training (RT) with Vitamin D
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo during Resistance training (RT)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AB) with Vitamin D
Number of subjects: 13
Study: 24332524

Group type: EXPERIMENTAL
Intervention: Oligofructose-enriched inulin (10 g/d)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Maltodextrin (10 g/d)
Number of subjects: 52
Study: 21877913

Group type: EXPERIMENTAL
Intervention: Basal insulin monotherapy (n=27)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion (CSII) (n=32)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 59
Study: 19164492

Group type: EXPERIMENTAL
Intervention: Extended-release bupropion (150-300 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18315510

Group type: EXPERIMENTAL
Intervention: Relaxation response training (stress management)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Lifestyle modification (control)
Number of subjects: 122
Study: 16389916

Group type: EXPERIMENTAL
Intervention: Test drug
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Penalty-free interim analysis strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivating studies
Number of subjects: 0
Study: 12362231

Group type: EXPERIMENTAL
Intervention: Oral E(2) 1 mg (oE(2) group, n = 37)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Oral E(2) 1 mg combined with gestodene 25 micro g (oE(2) + G group, n = 33)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐oestradiol (E(2)) 50 micro g (tE(2) group, n = 33)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo (n = 49)
Number of subjects: 152
Study: 10399995

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study: 8991841

Group type: EXPERIMENTAL
Intervention: Laparoscopy‐assisted vaginal hysterectomy (LAVH)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Abdominal hysterectomy (abd. HE)
Number of subjects: 70
Study: 1309390

Group type: EXPERIMENTAL
Intervention: 0.1 ml of iodized oil (47 mg of iodine)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 0.25 ml of iodized oil (118 mg of iodine)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 6697117

Group type: EXPERIMENTAL
Intervention: Antrectomy and Roux‐en‐Y anastomosis (Group B)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Nissen fundoplication (Group A)
Number of subjects: 42
Study: 31780001

Group type: EXPERIMENTAL
Intervention: Nasal spray containing IND02 (100 μg/100 μL), twice a day for seven days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 0
Study: 30165761

Group type: EXPERIMENTAL
Intervention: Digital Inclinometer
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Modified 35° MAG
Number of subjects: 270

Group type: COMPARATOR
Intervention: Freehand
Number of subjects: 270
Study: 26985911

Group type: EXPERIMENTAL
Intervention: Adherent interventions to the Clinical Treatment Algorithm (CTA)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Nonadherent interventions to the Clinical Treatment Algorithm (CTA)
Number of subjects: 454
Study: 25468575

Group type: EXPERIMENTAL
Intervention: Warmed i-gel (42°C for 30 minutes)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Room temperature i-gel (approximately 23°C)
Number of subjects: 68
Study: 22402822

Group type: EXPERIMENTAL
Intervention: PET imaging
Number of subjects: 91
Study: 20018537

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral glucose
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (oral water)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Facilitated tucking by parents (FTP)
Number of subjects: 18
Study: 18702647

Group type: EXPERIMENTAL
Intervention: Long-term virological response (LTR)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Nonresponders (NR)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Overall cohort (LTR + NR)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Adjusted for baseline risk factors
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Factors associated with IFG-DM
Number of subjects: 202
Study: 15998276

Group type: EXPERIMENTAL
Intervention: CHX rinsing
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cervitec varnish
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: EC40 varnish
Number of subjects: 16

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 16
Study: 12427056

Group type: EXPERIMENTAL
Intervention: Verteporfin therapy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 88
Study: 10687503

Group type: EXPERIMENTAL
Intervention: Remineralizing toothpaste
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional fluoride dentifrice
Number of subjects: 50